The Food and Drug Administration has scheduled an expert panel Thursday to define a process for updating COVID-19 shots annually. The goal is to create a long-term strategy as the virus shifts into new strains. (Axios)

Finch Therapeutics announced it will drop a Phase III trial for its donor stool-in-a-capsule for C. diff and lay off 95% of its employees. The company said it will focus on “realizing the value of its intellectual property estate and other assets” instead. (Endpoints News)

Long COVID has kept a significant chunk of Americans out of the workforce, a recent study found. 71% of people deemed to have long COVID required continuing medical treatment, or couldn’t work for six months or more, the results show. (The New York Times)

An innovative type of gene therapy that can deliver treatment directly to the brain has recently been approved in Europe and the U.K. for AADC deficiency, and at least one drugmaker is seeking U.S. approval. The type of gene therapy is also being studied to treat Alzheimer’s, Parkinson’s and Huntington’s. (STAT News)

A laboratory study unraveled ways non-antibiotic drugs can contribute to drug resistance. Globally, antibiotic resistance is a significant public health threat. An estimated 1.2 million people died as a direct result of it in 20192, and that number is predicted to climb. (Nature